Regulatory role of natural killer T cells in diabetes

Biomedical Journal

Volumn 38, Issue 6, 2015, Pages 484-495

  Tard, Celine ^a,b,c   Rouxel, Ophelie ^a,b,c   Lehuen, Agnes ^a,b,c  

^a INSTITUT COCHIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Sorbonne Paris Cité ^*  (France)

Author keywords

Autoimmunity; Diabetes; Immune regulation; Metabolism; NKT

Indexed keywords

CYTOKINE;

ANIMAL; CELL DIFFERENTIATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMAN; IMMUNOLOGY; MICROFLORA; MOUSE; NATURAL KILLER T CELL; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; CYTOKINES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; MICE; MICROBIOTA; NATURAL KILLER T-CELLS;

EID: 84980395486     PISSN: 23194170     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bj.2015.04.001     Document Type: Review

References (89)

1. Atkinson, M.A., Eisenbarth, G.S., Michels, A.W., Type 1 diabetes. Lancet 383 (2014), 69–82.
2. Diana, J., Simoni, Y., Furio, L., Beaudoin, L., Agerberth, B., Barrat, F., et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med 19 (2013), 65–73.
3. Lehuen, A., Diana, J., Zaccone, P., Cooke, A., Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 10 (2010), 501–513.
4. Willcox, A., Richardson, S.J., Bone, A.J., Foulis, A.K., Morgan, N.G., Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 155 (2009), 173–181.
5. Delovitch, T.L., Singh, B., The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7 (1997), 727–738.
6. Anderson, M.S., Bluestone, J.A., The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23 (2005), 447–485.
7. Zhen, Y., Sun, L., Liu, H., Duan, K., Zeng, C., Zhang, L., et al. Alterations of peripheral CD4+CD25+Foxp3+ T regulatory cells in mice with STZ-induced diabetes. Cell Mol Immunol 9 (2012), 75–85.
8. Mahler, R.J., Adler, M.L., Clinical review 102: type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 84 (1999), 1165–1171.
9. Kahn, S.E., Cooper, M.E., Del Prato, S., Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383 (2014), 1068–1083.
10. Bendelac, A., Rivera, M.N., Park, S.H., Roark, J.H., Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 15 (1997), 535–562.
11. Bendelac, A., Savage, P.B., Teyton, L., The biology of NKT cells. Annu Rev Immunol 25 (2007), 297–336.
12. Simoni, Y., Diana, J., Ghazarian, L., Beaudoin, L., Lehuen, A., Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?. Clin Exp Immunol 171 (2013), 8–19.
13. Kronenberg, M., Gapin, L., The unconventional lifestyle of NKT cells. Nat Rev Immunol 2 (2002), 557–568.
14. Jahng, A., Maricic, I., Aguilera, C., Cardell, S., Halder, R.C., Kumar, V., Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 199 (2004), 947–957.
15. Arrenberg, P., Halder, R., Dai, Y., Maricic, I., Kumar, V., Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc Natl Acad Sci U S A 107 (2010), 10984–10989.
16. Treiner, E., Duban, L., Bahram, S., Radosavljevic, M., Wanner, V., Tilloy, F., et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 422 (2003), 164–169.
17. Diana, J., Lehuen, A., NKT cells: friend or foe during viral infections?. Eur J Immunol 39 (2009), 3283–3291.
18. Tupin, E., Kinjo, Y., Kronenberg, M., The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 5 (2007), 405–417.
19. Cohen, N.R., Garg, S., Brenner, M.B., Antigen presentation by CD1 lipids, T cells, and NKT cells in microbial immunity. Adv Immunol 102 (2009), 1–94.
20. Mieza, M.A., Itoh, T., Cui, J.Q., Makino, Y., Kawano, T., Tsuchida, K., et al. Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol 156 (1996), 4035–4040.
21. Takeda, K., Dennert, G., The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 177 (1993), 155–164.
22. Gombert, J.M., Herbelin, A., Tancrède-Bohin, E., Dy, M., Carnaud, C., Bach, J.F., Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol 26 (1996), 2989–2998.
23. Hammond, K.J., Pellicci, D.G., Poulton, L.D., Naidenko, O.V., Scalzo, A.A., Baxter, A.G., et al. CD1d-restricted NKT cells: an interstrain comparison. J Immunol 167 (2001), 1164–1173.
24. Kojo, S., Adachi, Y., Keino, H., Taniguchi, M., Sumida, T., Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 44 (2001), 1127–1138.
25. Illés, Z., Kondo, T., Newcombe, J., Oka, N., Tabira, T., Yamamura, T., Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 164 (2000), 4375–4381.
26. Kukreja, A., Cost, G., Marker, J., Zhang, C., Sun, Z., Lin-Su, K., et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 109 (2002), 131–140.
27. Sumida, T., Sakamoto, A., Murata, H., Makino, Y., Takahashi, H., Yoshida, S., et al. Selective reduction of T cells bearing invariant V alpha 24J alpha Q antigen receptor in patients with systemic sclerosis. J Exp Med 182 (1995), 1163–1168.
28. Van der Vliet, H.J., von Blomberg, B.M., Nishi, N., Reijm, M., Voskuyl, A.E., van Bodegraven, A.A., et al. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 100 (2001), 144–148.
29. Kikutani, H., Makino, S., The murine autoimmune diabetes model: NOD and related strains. Adv Immunol 51 (1992), 285–322.
30. Godfrey, D.I., Kinder, S.J., Silvera, P., Baxter, A.G., Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR-CD8- thymocytes. J Autoimmun 10 (1997), 279–285.
31. Wang, B., Geng, Y.B., Wang, C.R., CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 194 (2001), 313–320.
32. Lehuen, A., Lantz, O., Beaudoin, L., Laloux, V., Carnaud, C., Bendelac, A., et al. Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 188 (1998), 1831–1839.
33. Cain, J.A., Smith, J.A., Ondr, J.K., Wang, B., Katz, J.D., NKT cells and IFN-gamma establish the regulatory environment for the control of diabetogenic T cells in the nonobese diabetic mouse. J Immunol 176 (2006), 1645–1654.
34. Beaudoin, L., Laloux, V., Novak, J., Lucas, B., Lehuen, A., NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells. Immunity 17 (2002), 725–736.
35. Sharif, S., Arreaza, G.A., Zucker, P., Mi, Q.S., Sondhi, J., Naidenko, O.V., et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 7 (2001), 1057–1062.
36. Rapoport, M.J., Jaramillo, A., Zipris, D., Lazarus, A.H., Serreze, D.V., Leiter, E.H., et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 178 (1993), 87–99.
37. Laloux, V., Beaudoin, L., Jeske, D., Carnaud, C., Lehuen, A.N.K., T cell-induced protection against diabetes in V alpha 14-J alpha 281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen. J Immunol 166 (2001), 3749–3756.
38. Hammond, K.J., Poulton, L.D., Palmisano, L.J., Silveira, P.A., Godfrey, D.I., Baxter, A.G., alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 187 (1998), 1047–1056.
39. Laloux, V., Beaudoin, L., Ronet, C., Lehuen, A., Phenotypic and functional differences between NKT cells colonizing splanchnic and peripheral lymph nodes. J Immunol Balt 168 (2002), 3251–3258.
40. Beaudoin, L., Diana, J., Ghazarian, L., Simoni, Y., Boitard, C., Lehuen, A., Plasmacytoid dendritic cells license regulatory T cells, upon iNKT-cell stimulation, to prevent autoimmune diabetes. Eur J Immunol 44 (2014), 1454–1466.
41. Falcone, M., Facciotti, F., Ghidoli, N., Monti, P., Olivieri, S., Zaccagnino, L., et al. Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice. J Immunol Balt 172 (2004), 5908–5916.
42. Ghazarian, L., Diana, J., Beaudoin, L., Larsson, P.G., Puri, R.K., van Rooijen, N., et al. Protection against type 1 diabetes upon Coxsackievirus B4 infection and iNKT-cell stimulation: role of suppressive macrophages. Diabetes 62 (2013), 3785–3796.
43. Chen, G., Han, G., Wang, J., Wang, R., Xu, R., Shen, B., et al. Natural killer cells modulate overt autoimmunity to homeostasis in nonobese diabetic mice after anti-CD3 F(ab')2 antibody treatment through secreting transforming growth factor-β. Am J Pathol 175 (2009), 1086–1094.
44. Höglund, P., Mintern, J., Waltzinger, C., Heath, W., Benoist, C., Mathis, D., Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 189 (1999), 331–339.
45. Ghazarian, L., Diana, J., Simoni, Y., Beaudoin, L., Lehuen, A., Prevention or acceleration of type 1 diabetes by viruses. Cell Mol Life Sci 70 (2013), 239–255.
46. Diana, J., Brezar, V., Beaudoin, L., Dalod, M., Mellor, A., Tafuri, A., et al. Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay. J Exp Med 208 (2011), 729–745.
47. Chen, Y.G., Choisy-Rossi, C.-M., Holl, T.M., Chapman, H.D., Besra, G.S., Porcelli, S.A., et al. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 174 (2005), 1196–1204.
48. Spolski, R., Leonard, W.J., Cytokine mediators of Th17 function. Eur J Immunol 39 (2009), 658–661.
49. Happel, K.I., Zheng, M., Young, E., Quinton, L.J., Lockhart, E., Ramsay, A.J., et al. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol Balt 170 (2003), 4432–4436.
50. Shibata, K., Yamada, H., Hara, H., Kishihara, K., Yoshikai, Y., Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J Immunol 178 (2007), 4466–4472.
51. Doisne, J.M., Becourt, C., Amniai, L., Duarte, N., Le Luduec, J.B., Eberl, G., et al. Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor (gamma)t+ and respond preferentially under inflammatory conditions. J Immunol Balt 183 (2009), 2142–2149.
52. Michel, M.L., Keller, A.C., Paget, C., Fujio, M., Trottein, F., Savage, P.B., et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 204 (2007), 995–1001.
53. Doisne, J.M., Soulard, V., Bécourt, C., Amniai, L., Henrot, P., Havenar-Daughton, C., et al. Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1- invariant NKT cells to bacteria. J Immunol Balt 186 (2011), 662–666.
54. Simoni, Y., Gautron, A.S., Beaudoin, L., Bui, L.C., Michel, M.L., Coumoul, X., et al. NOD mice contain an elevated frequency of iNKT17 cells that exacerbate diabetes. Eur J Immunol 41 (2011), 3574–3585.
55. Ghazarian, L., Simoni, Y., Magalhaes, I., Lehuen, A., Invariant NKT cell development: focus on NOD mice. Curr Opin Immunol 27 (2014), 83–88.
56. Li, S., Joseph, C., Becourt, C., Klibi, J., Luce, S., Dubois-Laforgue, D., et al. Potential role of IL-17-producing iNKT cells in type 1 diabetes. PloS One, 9, 2014, e96151.
57. Esteban, L.M., Tsoutsman, T., Jordan, M.A., Roach, D., Poulton, L.D., Brooks, A., et al. Genetic control of NKT cell numbers maps to major diabetes and lupus loci. J Immunol Balt 171 (2003), 2873–2878.
58. Fletcher, J.M., Jordan, M.A., Snelgrove, S.L., Slattery, R.M., Dufour, F.D., Kyparissoudis, K., et al. Congenic analysis of the NKT cell control gene Nkt2 implicates the peroxisomal protein Pxmp4. J Immunol Balt 181 (2008), 3400–3412.
59. Facciotti, F., Ramanjaneyulu, G.S., Lepore, M., Sansano, S., Cavallari, M., Kistowska, M., et al. Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus. Nat Immunol 13 (2012), 474–480.
60. Gumperz, J.E., Miyake, S., Yamamura, T., Brenner, M.B., Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195 (2002), 625–636.
61. Montoya, C.J., Pollard, D., Martinson, J., Kumari, K., Wasserfall, C., Mulder, C.B., et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 122 (2007), 1–14.
62. Lee, P.T., Benlagha, K., Teyton, L., Bendelac, A., Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 195 (2002), 637–641.
63. Hegde, S., Lockridge, J.L., Becker, Y.A., Ma, S., Kenney, S.C., Gumperz, J.E., Human NKT cells direct the differentiation of myeloid APCs that regulate T cell responses via expression of programmed cell death ligands. J Autoimmun 37 (2011), 28–38.
64. Roman-Gonzalez, A., Moreno, M.E., Alfaro, J.M., Uribe, F., Latorre-Sierra, G., Rugeles, M.T., et al. Frequency and function of circulating invariant NKT cells in autoimmune diabetes mellitus and thyroid diseases in Colombian patients. Hum Immunol 70 (2009), 262–268.
65. Wilson, S.B., Kent, S.C., Patton, K.T., Orban, T., Jackson, R.A., Exley, M., et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 391 (1998), 177–181.
66. Lee, P.T., Putnam, A., Benlagha, K., Teyton, L., Gottlieb, P.A., Bendelac, A., Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 110 (2002), 793–800.
67. Kent, S.C., Chen, Y., Clemmings, S.M., Viglietta, V., Kenyon, N.S., Ricordi, C., et al. Loss of IL-4 secretion from human type 1a diabetic pancreatic draining lymph node NKT cells. J Immunol Balt 175 (2005), 4458–4464.
68. Chang, D.H., Osman, K., Connolly, J., Kukreja, A., Krasovsky, J., Pack, M., et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201 (2005), 1503–1517.
69. Blumenfeld, H.J., Tohn, R., Haeryfar, S.M., Liu, Y., Savage, P.B., Delovitch, T.L., Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice. Clin Exp Immunol 166 (2011), 121–133.
70. Motohashi, S., Ishikawa, A., Ishikawa, E., Otsuji, M., Iizasa, T., Hanaoka, H., et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12 (2006), 6079–6086.
71. Giongo, A., Gano, K.A., Crabb, D.B., Mukherjee, N., Novelo, L.L., Casella, G., et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J 5 (2011), 82–91.
72. Brown, C.T., Davis-Richardson, A.G., Giongo, A., Gano, K.A., Crabb, D.B., Mukherjee, N., et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PloS One, 6, 2011, e25792.
73. Sorini, C., Falcone, M., Shaping the (auto)immune response in the gut: the role of intestinal immune regulation in the prevention of type 1 diabetes. Am J Clin Exp Immunol 2 (2013), 156–171.
74. Kostic, A.D., Gevers, D., Siljander, H., Vatanen, T., Hyötyläinen, T., Hämäläinen, A.M., et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe 17 (2015), 260–273.
75. Loh, L., Ivarsson, M.A., Michaëlsson, J., Sandberg, J.K., Nixon, D.F., Invariant natural killer T cells developing in the human fetus accumulate and mature in the small intestine. Mucosal Immunol 7 (2014), 1233–1243.
76. Zeissig, S., Blumberg, R.S., Commensal microbiota and NKT cells in the control of inflammatory diseases at mucosal surfaces. Curr Opin Immunol 25 (2013), 690–696.
77. Markle, J.G., Frank, D.N., Mortin-Toth, S., Robertson, C.E., Feazel, L.M., Rolle-Kampczyk, U., et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 339 (2013), 1084–1088.
78. Terabe, M., Swann, J., Ambrosino, E., Sinha, P., Takaku, S., Hayakawa, Y., et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 202 (2005), 1627–1633.
79. Duarte, N., Stenström, M., Campino, S., Bergman, M.L., Lundholm, M., Holmberg, D., et al. Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells. J Immunol Balt 173 (2004), 3112–3118.
80. Subramanian, L., Blumenfeld, H., Tohn, R., Ly, D., Aguilera, C., Maricic, I., et al. NKT cells stimulated by long fatty acyl chain sulfatides significantly reduce the incidence of type 1 diabetes in nonobese diabetic mice [corrected]. PloS One, 7, 2012, e37771.
81. Kadri, N., Korpos, E., Gupta, S., Briet, C., Löfbom, L., Yagita, H., et al. CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes. J Immunol Balt 188 (2012), 3138–3149.
82. Mathis, D., Immunological goings-on in visceral adipose tissue. Cell Metab 17 (2013), 851–859.
83. Tateya, S., Kim, F., Tamori, Y., Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne), 4, 2013, 93.
84. Lynch, L., O'Shea, D., Winter, D.C., Geoghegan, J., Doherty, D.G., O'Farrelly, C., Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur J Immunol 39 (2009), 1893–1901.
85. Lynch, L., Nowak, M., Varghese, B., Clark, J., Hogan, A.E., Toxavidis, V., et al. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 37 (2012), 574–587.
86. Lynch, L., Michelet, X., Zhang, S., Brennan, P.J., Moseman, A., Lester, C., et al. Regulatory iNKT cells lack expression of the transcription factor PLZF and control the homeostasis of T(reg) cells and macrophages in adipose tissue. Nat Immunol 16 (2015), 85–95.
87. Schipper, H.S., Rakhshandehroo, M., van de Graaf, S.F.J., Venken, K., Koppen, A., Stienstra, R., et al. Natural killer T cells in adipose tissue prevent insulin resistance. J Clin Invest 122 (2012), 3343–3354.
88. Ohmura, K., Ishimori, N., Ohmura, Y., Tokuhara, S., Nozawa, A., Horii, S., et al. Natural killer T cells are involved in adipose tissues inflammation and glucose intolerance in diet-induced obese mice. Arterioscler Thromb Vasc Biol 30 (2010), 193–199.
89. Mantell, B.S., Stefanovic-Racic, M., Yang, X., Dedousis, N., Sipula, I.J., O'Doherty, R.M., Mice lacking NKT cells but with a complete complement of CD8+ T-cells are not protected against the metabolic abnormalities of diet-induced obesity. PloS One, 6, 2011, e19831.